<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863655</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001Y2301</org_study_id>
    <secondary_id>2008-008698-69</secondary_id>
    <nct_id>NCT00863655</nct_id>
  </id_info>
  <brief_title>Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole</brief_title>
  <acronym>BOLERO-2</acronym>
  <official_title>A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no treatments specifically approved after recurrence or progression on a non
      steroidal aromatase inhibitors (NSAI). In light of the need for new treatment options for
      postmenopausal women after failure of prior NSAI therapy, the purpose of this Phase III study
      is to compare efficacy and safety of a treatment with exemestane + everolimus to exemestane +
      placebo in postmenopausal women with estrogen receptor positive locally advanced or
      metastatic breast cancer refractory to NSAI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2009</start_date>
  <completion_date type="Actual">December 4, 2014</completion_date>
  <primary_completion_date type="Actual">December 4, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments.</measure>
    <time_frame>date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months</time_frame>
    <description>Progression-free survival, the primary endpoint in this study, is defined as the time from the date of randomization to the date of first documented radiological progression or death due to any cause. Disease progression was based on the tumor assessment by the local radiologist or investigator using RECIST 1.0 criteria. If a patient did not progress or known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. For patients with lytic or mixed (lytic+sclerotic) bone lesions, the following is considered progression: appearance of ≥1 new lytic lesions in bone; the appearance of ≥ new lesions outside of bone and unequivocal progression of existing bone lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) by Number of Deaths</measure>
    <time_frame>up to 53 months</time_frame>
    <description>Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause. If a patient is not known to have died, survival was censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) by Median</measure>
    <time_frame>up to 53 months</time_frame>
    <description>Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 21 months</time_frame>
    <description>Overall response rate (ORR) is the percentage of patients with a best overall response of complete response (CR) or partial response (PR) according to RECIST 1.0. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>up to 21 months</time_frame>
    <description>CBR is defined as the percentage of patients with best overall response of either complete response (CR), a partial response (PR) or stable disease (SD) &gt;= 24 weeks, according to RECIST 1.0. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD = Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD; PD = At least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With no Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Using Kaplan-Meier</measure>
    <time_frame>2, 4, 6, 9 months</time_frame>
    <description>The ECOG PS (Eastern Cooperative Oncology Group Performance Scale) is a standard criteria for measuring how treatment of cancer impacts level of functioning in terms of the ability to care for oneself, daily activity, &amp; physical ability (walking, working, etc.). Scale score ranges:0 to 5, 5 being the worst. Scale index: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory &amp; able to carry out work of a light or sedentary nature. 2: Ambulatory &amp; capable of all self-care but unable to carry out any work activities. Up &amp; about more than 50% of waking hours. 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4 - Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5 - Dead. A deterioration of ECOG is an increase of 1 of the ECOG PS without improvement back to initial level at a subsequent time of measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Outcomes (PROs): Time to Deterioration of PRO Scores Using Kaplan Meier - EORTC QLQ-C30</measure>
    <time_frame>Up to 21 months</time_frame>
    <description>The QLQ-C30 is composed of both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status - QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than 1 scale. All of the scales measures range in score from 0 to 100. A high scale score = higher response level. Thus a high score for a functional scale represents a healthy level of function, a high score for the global health status / QoL represents a high quality of life but a high score for a symptom scale / item represents a high level of symptomatology / problems. The principle for scoring these scales: 1.) Estimate the average of the items that contribute to the scale = raw score. 2.) Linear transformation to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher (&quot;better&quot;) level of functioning, or a higher (&quot;worse&quot;) level of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Having no Overall Response Based on Investigator Assessment</measure>
    <time_frame>2, 4, 6, 9 months</time_frame>
    <description>overall response = complete response (CR) + partial response (PR) per RECIST 1.0 Time to overall response (CR or PR) based on investigator is the time between date of randomization/start of treatment until first documented response (CR or PR). This analysis included all patients/responders. Patients who did not achieve a confirmed PR or CR were censored at last adequate tumor assessment date when they did not progress. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (Among Participants With Best Overall Response of CR or PR) Estimated Per Kaplan-Meier</measure>
    <time_frame>21 months</time_frame>
    <description>Duration of response of CR or PR based on investigator applies only to patients whose best overall response was CR or PR (RECIST 1.0). The start date was the date of first documented response (CR or PR) and the end date and censoring is defined the same as that for time to progression. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Everolimus Concentrations at Week 4</measure>
    <time_frame>pre-dose, 2 hours post-dose</time_frame>
    <description>Characterize the pharmacokinetics (PK) of everolimus in combination with exemestane using Cmin (pre-dose) and C2h (post-dose) at week 4 in a small group of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exemestane Concentrations at Week 4</measure>
    <time_frame>predose, 2 hours post-dose</time_frame>
    <description>Characterize the PK of exemestane in combination with or without everolimus using Cmin and C2h at week 4 in a small group of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol Plasma Concentrations</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Compare estradiol concentrations from baseline to week 4 in both treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">724</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus + Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Exemestane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.</description>
    <arm_group_label>Everolimus + Exemestane</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane 25 mg orally daily.</description>
    <arm_group_label>Everolimus + Exemestane</arm_group_label>
    <arm_group_label>Placebo + Exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus Placebo</intervention_name>
    <description>Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.</description>
    <arm_group_label>Placebo + Exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult women (≥ 18 years of age) with metastatic or locally advanced breast cancer not
             amenable to curative treatment by surgery or radiotherapy.

          -  Histological or cytological confirmation of estrogen-receptor positive (ER+) breast
             cancer

          -  Postmenopausal women.

          -  Disease refractory to non steroidal aromatase inhibitors (NSAI),

          -  Radiological or clinical evidence of recurrence or progression on or after the last
             systemic therapy prior to randomization.

          -  Patients must have at least one lesion that can be accurately measured or bone lesions
             in the absence of measurable disease as defined above.

        Exclusion Criteria:

          -  HER2-overexpressing patients

          -  Patients with only non-measurable lesions other than bone metastasis (e.g. pleural
             effusion, ascites etc.).

          -  Patients who received more than one chemotherapy line for Advanced Breast Cancer.

          -  Previous treatment with exemestane or mTOR inhibitors.

          -  Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).

          -  Radiotherapy within four weeks prior to randomization

          -  Currently receiving hormone replacement therapy,

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Centers</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group DeptofHighlandsOncologyGrp(2)</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center Dept. of CBCC (3)</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates Dept.ofCancerCareAssoc. (2)</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grass Valley Hematology Oncology Medical Group Dept. of Grass Valley Hem/Onc</name>
      <address>
        <city>Grass Valley</city>
        <state>California</state>
        <zip>95945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic SC</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital SharpClinicalOncologyResearch</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Oncology/Pinnacle Oncology Hematology Dept.ofPremiereOncologyAZ</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare Dept. of RRMG (4)</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>94503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center - Boca Raton Deerfield Beach</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33248</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Research Institute</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists DeptofFloridaCancerSpecialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital Memorial Cancer Institute</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Cancer Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic PA Dept.ofFloridaMedicalClinic</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists. Drug Ship</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center Study Coordinator</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, SC Dept.of Oncology Specialists</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068-0736</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Center</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas Dept.ofCancerCtr.ofKansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville / James Graham Brown Cancer Center SC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic Hematology Oncology Clinic (2)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent City Research Consortium, LLC Dept of Hem&amp;Onc Specialist - 2</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Health System Research Institute Wayson Pavilion</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center Medical Oncology &amp; Hematology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institute at Franklin Square Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237-3998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Hematology/Oncology Associates, P.A.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick Memorial Hospital Dept. of FMH-IRB</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital Holy Cross</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Dept of Lahey Clinic (2)</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Medical Oncology Clinic</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Cancer &amp; Breast Institute Dept.ofSt.LouisCancer&amp;Breast</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Nebraska Oncology Cancer Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates Dept. of the CCHD</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinitas Comprehensive Cancer Center Dept. of Trinitas</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Research Center Dept of UNM Cancer &amp; Research</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance Dept.ofArenaOncologyAssoc(2)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProHealth Care</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center Dept.ofBeth Israel Med. Ctr(2)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College Weill Cornell Med. Ctr.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Association of Rockland</name>
      <address>
        <city>Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marion L. Shepard Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>North Carolina</state>
        <zip>27889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Southwest Oklahoma Cancer Research Dept.of Southwest Oklahoma</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates SC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State University / Milton S. Hershey Medical Center Division of Oncology (2)</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina -Hollings Cancer Center Dept. MUSC/HollingsCancerCtr</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(5)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center SimmonsComprehensiveCancerCtr.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders Dept. of The Ctr for C &amp; BD(2)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(2)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Oncology HOPE Richardson</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Utah Cancer Associates SC</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403-3105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Utah Clinic CRAD001Y2301</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists Dept.of Utah Cancer Spec. (2)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah / Huntsman Cancer Institute Dept.ofHuntsmanCancerInst.(2)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology &amp; Hematology Associates of Northern VA Med. Onc&amp;Hem Assoc. of No.VA</name>
      <address>
        <city>Reston</city>
        <state>Virginia</state>
        <zip>20190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital &amp; Clinics UW ComprehensiveCancerCtr(2)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <zip>4020</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>41825-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uberlândia</city>
        <state>MG</state>
        <zip>38408-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20230-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90560-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 3G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>J7Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2S 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Weston</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <state>CZE</state>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>14044</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Menoufiya</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Roche sur Yon Cedex</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen Cedex 1</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Herblain Cédex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong SAR</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szolnok</city>
        <zip>H-5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brindisi</city>
        <state>BR</state>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antella - Bagno a Ripoli</city>
        <state>FI</state>
        <zip>50011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Macerata</city>
        <state>MC</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saronno</city>
        <state>Va</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi-city</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Isehara-city</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>01812</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1090 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lørenskog</city>
        <zip>NO-1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-108</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-125</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lleida</city>
        <state>Cataluna</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terrassa</city>
        <state>Catalunya</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Altunizade</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Broomfield</city>
        <state>Chelmsford</state>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bolerobreastcancertrials.com</url>
    <description>Visit NovartisClinicalTrials.com: Pre-qualify for a trial, and view a list of trials and participating study centers.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <results_first_submitted>July 31, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2012</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Estrogen Receptor positive</keyword>
  <keyword>ER+</keyword>
  <keyword>exemestane</keyword>
  <keyword>mTOR</keyword>
  <keyword>everolimus</keyword>
  <keyword>refractory</keyword>
  <keyword>NSAI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although 724 patients were randomized, 4 never received any study treatment and thus were excluded form the safety set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Everolimus + Exemestane</title>
          <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Exemestane</title>
          <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="485"/>
                <participants group_id="P2" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Completed means discontinued the treatment period.</participants>
                <participants group_id="P2" count="0">Completed means discontinued the treatment period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="485"/>
                <participants group_id="P2" count="239"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New cancer therapy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="221"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment completed as per protocol</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus + Exemestane</title>
          <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Exemestane</title>
          <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="485"/>
            <count group_id="B2" value="239"/>
            <count group_id="B3" value="724"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="10.31"/>
                    <measurement group_id="B2" value="61.2" spread="9.75"/>
                    <measurement group_id="B3" value="62.1" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="485"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="724"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments.</title>
        <description>Progression-free survival, the primary endpoint in this study, is defined as the time from the date of randomization to the date of first documented radiological progression or death due to any cause. Disease progression was based on the tumor assessment by the local radiologist or investigator using RECIST 1.0 criteria. If a patient did not progress or known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. For patients with lytic or mixed (lytic+sclerotic) bone lesions, the following is considered progression: appearance of ≥1 new lytic lesions in bone; the appearance of ≥ new lesions outside of bone and unequivocal progression of existing bone lesions.</description>
        <time_frame>date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months</time_frame>
        <population>All randomized patients were included in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments.</title>
          <description>Progression-free survival, the primary endpoint in this study, is defined as the time from the date of randomization to the date of first documented radiological progression or death due to any cause. Disease progression was based on the tumor assessment by the local radiologist or investigator using RECIST 1.0 criteria. If a patient did not progress or known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. For patients with lytic or mixed (lytic+sclerotic) bone lesions, the following is considered progression: appearance of ≥1 new lytic lesions in bone; the appearance of ≥ new lesions outside of bone and unequivocal progression of existing bone lesions.</description>
          <population>All randomized patients were included in the Full Analysis Set.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" lower_limit="6.44" upper_limit="8.05"/>
                    <measurement group_id="O2" value="2.83" lower_limit="2.76" upper_limit="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) by Number of Deaths</title>
        <description>Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause. If a patient is not known to have died, survival was censored at the date of last contact.</description>
        <time_frame>up to 53 months</time_frame>
        <population>All randomized patients were included in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) by Number of Deaths</title>
          <description>Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause. If a patient is not known to have died, survival was censored at the date of last contact.</description>
          <population>All randomized patients were included in the Full Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) by Median</title>
        <description>Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause.</description>
        <time_frame>up to 53 months</time_frame>
        <population>All randomized patients were included in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) by Median</title>
          <description>Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause.</description>
          <population>All randomized patients were included in the Full Analysis Set.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.98" lower_limit="27.96" upper_limit="34.56"/>
                    <measurement group_id="O2" value="26.55" lower_limit="22.57" upper_limit="33.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Overall response rate (ORR) is the percentage of patients with a best overall response of complete response (CR) or partial response (PR) according to RECIST 1.0. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.</description>
        <time_frame>up to 21 months</time_frame>
        <population>All randomized patients were included in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Overall response rate (ORR) is the percentage of patients with a best overall response of complete response (CR) or partial response (PR) according to RECIST 1.0. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.</description>
          <population>All randomized patients were included in the Full Analysis Set.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate (CBR)</title>
        <description>CBR is defined as the percentage of patients with best overall response of either complete response (CR), a partial response (PR) or stable disease (SD) &gt;= 24 weeks, according to RECIST 1.0. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD = Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD; PD = At least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline.</description>
        <time_frame>up to 21 months</time_frame>
        <population>All randomized patients were included in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR)</title>
          <description>CBR is defined as the percentage of patients with best overall response of either complete response (CR), a partial response (PR) or stable disease (SD) &gt;= 24 weeks, according to RECIST 1.0. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD = Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD; PD = At least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline.</description>
          <population>All randomized patients were included in the Full Analysis Set.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4"/>
                    <measurement group_id="O2" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With no Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Using Kaplan-Meier</title>
        <description>The ECOG PS (Eastern Cooperative Oncology Group Performance Scale) is a standard criteria for measuring how treatment of cancer impacts level of functioning in terms of the ability to care for oneself, daily activity, &amp; physical ability (walking, working, etc.). Scale score ranges:0 to 5, 5 being the worst. Scale index: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory &amp; able to carry out work of a light or sedentary nature. 2: Ambulatory &amp; capable of all self-care but unable to carry out any work activities. Up &amp; about more than 50% of waking hours. 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4 - Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5 - Dead. A deterioration of ECOG is an increase of 1 of the ECOG PS without improvement back to initial level at a subsequent time of measurement.</description>
        <time_frame>2, 4, 6, 9 months</time_frame>
        <population>All randomized patients were included in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With no Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Using Kaplan-Meier</title>
          <description>The ECOG PS (Eastern Cooperative Oncology Group Performance Scale) is a standard criteria for measuring how treatment of cancer impacts level of functioning in terms of the ability to care for oneself, daily activity, &amp; physical ability (walking, working, etc.). Scale score ranges:0 to 5, 5 being the worst. Scale index: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory &amp; able to carry out work of a light or sedentary nature. 2: Ambulatory &amp; capable of all self-care but unable to carry out any work activities. Up &amp; about more than 50% of waking hours. 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4 - Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5 - Dead. A deterioration of ECOG is an increase of 1 of the ECOG PS without improvement back to initial level at a subsequent time of measurement.</description>
          <population>All randomized patients were included in the Full Analysis Set.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="0.80" upper_limit="0.87"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.82" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.70" upper_limit="0.78"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.73" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="0.58" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.57" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.50" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.47" lower_limit="0.32" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-reported Outcomes (PROs): Time to Deterioration of PRO Scores Using Kaplan Meier - EORTC QLQ-C30</title>
        <description>The QLQ-C30 is composed of both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status - QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than 1 scale. All of the scales measures range in score from 0 to 100. A high scale score = higher response level. Thus a high score for a functional scale represents a healthy level of function, a high score for the global health status / QoL represents a high quality of life but a high score for a symptom scale / item represents a high level of symptomatology / problems. The principle for scoring these scales: 1.) Estimate the average of the items that contribute to the scale = raw score. 2.) Linear transformation to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher (&quot;better&quot;) level of functioning, or a higher (&quot;worse&quot;) level of symptoms.</description>
        <time_frame>Up to 21 months</time_frame>
        <population>All randomized patients were included in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-reported Outcomes (PROs): Time to Deterioration of PRO Scores Using Kaplan Meier - EORTC QLQ-C30</title>
          <description>The QLQ-C30 is composed of both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status - QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than 1 scale. All of the scales measures range in score from 0 to 100. A high scale score = higher response level. Thus a high score for a functional scale represents a healthy level of function, a high score for the global health status / QoL represents a high quality of life but a high score for a symptom scale / item represents a high level of symptomatology / problems. The principle for scoring these scales: 1.) Estimate the average of the items that contribute to the scale = raw score. 2.) Linear transformation to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher (&quot;better&quot;) level of functioning, or a higher (&quot;worse&quot;) level of symptoms.</description>
          <population>All randomized patients were included in the Full Analysis Set.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deterioration global health status score ≥ 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" lower_limit="4.17" upper_limit="5.68"/>
                    <measurement group_id="O2" value="4.40" lower_limit="3.58" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deterioration in PF domain score of ≥ 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" lower_limit="4.17" upper_limit="6.97"/>
                    <measurement group_id="O2" value="4.37" lower_limit="2.83" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deterioration in EF domain score of ≥ 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" lower_limit="5.55" upper_limit="8.41"/>
                    <measurement group_id="O2" value="6.93" lower_limit="4.17" upper_limit="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deterioration in SF domain score of ≥ 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.34" lower_limit="6.93" upper_limit="10.87"/>
                    <measurement group_id="O2" value="7.03" lower_limit="5.62">NA: Median time to definitive deterioration computed using Kaplan-Meier method.95% CIs calculated using Brookmeyer &amp; Crowley (1982) method. Therefore, upper boundary of 95% CI may not be estimable when median is close to the longest patient follow-up</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Having no Overall Response Based on Investigator Assessment</title>
        <description>overall response = complete response (CR) + partial response (PR) per RECIST 1.0 Time to overall response (CR or PR) based on investigator is the time between date of randomization/start of treatment until first documented response (CR or PR). This analysis included all patients/responders. Patients who did not achieve a confirmed PR or CR were censored at last adequate tumor assessment date when they did not progress. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.</description>
        <time_frame>2, 4, 6, 9 months</time_frame>
        <population>All randomized patients were included in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Having no Overall Response Based on Investigator Assessment</title>
          <description>overall response = complete response (CR) + partial response (PR) per RECIST 1.0 Time to overall response (CR or PR) based on investigator is the time between date of randomization/start of treatment until first documented response (CR or PR). This analysis included all patients/responders. Patients who did not achieve a confirmed PR or CR were censored at last adequate tumor assessment date when they did not progress. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.</description>
          <population>All randomized patients were included in the Full Analysis Set.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="485"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.94" upper_limit="0.98"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.97" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.91" upper_limit="0.95"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.97" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.89" upper_limit="0.94"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.97" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.88" upper_limit="0.93"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.97" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (Among Participants With Best Overall Response of CR or PR) Estimated Per Kaplan-Meier</title>
        <description>Duration of response of CR or PR based on investigator applies only to patients whose best overall response was CR or PR (RECIST 1.0). The start date was the date of first documented response (CR or PR) and the end date and censoring is defined the same as that for time to progression. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.</description>
        <time_frame>21 months</time_frame>
        <population>Randomized patients with best overall response of CR or PR.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (Among Participants With Best Overall Response of CR or PR) Estimated Per Kaplan-Meier</title>
          <description>Duration of response of CR or PR based on investigator applies only to patients whose best overall response was CR or PR (RECIST 1.0). The start date was the date of first documented response (CR or PR) and the end date and censoring is defined the same as that for time to progression. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.</description>
          <population>Randomized patients with best overall response of CR or PR.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.21" lower_limit="5.55">NA - upper limit was not estimable</measurement>
                    <measurement group_id="O2" value="NA">NA - median, lower and upper limit of the 95 % CI were not estimable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Everolimus Concentrations at Week 4</title>
        <description>Characterize the pharmacokinetics (PK) of everolimus in combination with exemestane using Cmin (pre-dose) and C2h (post-dose) at week 4 in a small group of patients.</description>
        <time_frame>pre-dose, 2 hours post-dose</time_frame>
        <population>Safety Set population consisted of all patients who received at least one dose of study treatment and who had at least one valid post-baseline safety assessment. Although the safety set was considered for the analysis (N), only participants (n) who had pre-dose &amp; 2 hours post-dose values for the given time points were analyzed for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Everolimus Concentrations at Week 4</title>
          <description>Characterize the pharmacokinetics (PK) of everolimus in combination with exemestane using Cmin (pre-dose) and C2h (post-dose) at week 4 in a small group of patients.</description>
          <population>Safety Set population consisted of all patients who received at least one dose of study treatment and who had at least one valid post-baseline safety assessment. Although the safety set was considered for the analysis (N), only participants (n) who had pre-dose &amp; 2 hours post-dose values for the given time points were analyzed for that time point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose (Cmin) (n:22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.04" spread="9.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (C2h) (n:24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.50" spread="17.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exemestane Concentrations at Week 4</title>
        <description>Characterize the PK of exemestane in combination with or without everolimus using Cmin and C2h at week 4 in a small group of patients.</description>
        <time_frame>predose, 2 hours post-dose</time_frame>
        <population>Safety Set population consisted of all patients who received at least one dose of study treatment and who had at least one valid post-baseline safety assessment. Although the safety set was considered for the analysis (N), only participants (n) who had pre-dose &amp; 2 hours post-dose values for the given time points were analyzed for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Exemestane Concentrations at Week 4</title>
          <description>Characterize the PK of exemestane in combination with or without everolimus using Cmin and C2h at week 4 in a small group of patients.</description>
          <population>Safety Set population consisted of all patients who received at least one dose of study treatment and who had at least one valid post-baseline safety assessment. Although the safety set was considered for the analysis (N), only participants (n) who had pre-dose &amp; 2 hours post-dose values for the given time points were analyzed for that time point.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose (Cmin) (n: 34, n: 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.474" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.43" spread="0.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (C2h) (n: 39, n: 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.16" spread="19.805" lower_limit="0.68" upper_limit="0.94"/>
                    <measurement group_id="O2" value="13.30" spread="11.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estradiol Plasma Concentrations</title>
        <description>Compare estradiol concentrations from baseline to week 4 in both treatment arms.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Safety Set population consisted of all patients who received at least one dose of study treatment and who had at least one valid post-baseline safety assessment. Although the safety set was considered for the analysis (N), only participants (n) who had pre-dose &amp; 2 hours post-dose values for the given time points were analyzed for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + Exemestane</title>
            <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Exemestane</title>
            <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estradiol Plasma Concentrations</title>
          <description>Compare estradiol concentrations from baseline to week 4 in both treatment arms.</description>
          <population>Safety Set population consisted of all patients who received at least one dose of study treatment and who had at least one valid post-baseline safety assessment. Although the safety set was considered for the analysis (N), only participants (n) who had pre-dose &amp; 2 hours post-dose values for the given time points were analyzed for that time point.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n: = 41, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.62" spread="3.342" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="4.09" spread="1.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n: 38, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="2.551" lower_limit="0.68" upper_limit="0.94"/>
                    <measurement group_id="O2" value="5.17" spread="6.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>4 patients were excluded from the Safety Set; all 4 of these patients (3 in the everolimus plus exemestane arm and 1 in the placebo plus exemestane group) were randomized but subsequently didn't receive study treatment and didn't have an AE reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Everolimus + Exemestane</title>
          <description>Everolimus 10 mg daily in combination with exemestane 25 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Exemestane</title>
          <description>Placebo of everolimus in combination with exemestane 25 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA V16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Retinal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Small intestine ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pyometra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pulmonary radiation injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pulmonary radiation injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Computerised tomogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Metastases to eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Preventive surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Preventive surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA V16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="479" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Constipation</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Nausea</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="281" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="286" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Back pain</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Headache</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Cough</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Rash</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="238"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="482"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

